|
05 Oct 2022 |
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
|
|
05 Oct 2022 |
SyntheX and Bristol Myers Squibb Enter Into a Research Collaboration to Discover and Develop Targeted Protein Degradation (TPD) Therapeutics
|
|
05 Oct 2022 |
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
|
|
04 Oct 2022 |
Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming
|
|
03 Oct 2022 |
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
|
|
03 Oct 2022 |
Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
|
|
30 Sep 2022 |
Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program
|
|
29 Sep 2022 |
Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc
|
|
28 Sep 2022 |
Sudo Biosciences Raises $37M Series A Financing to Advance Precision TYK2 Therapeutics
|
|
28 Sep 2022 |
Arsenal Biosciences Announces Joint Discovery Collaboration with Genentech to Identify Features of Successful T-Cell Therapies for Oncology
|
|
28 Sep 2022 |
Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer
|
|
22 Sep 2022 |
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
|
|
21 Sep 2022 |
Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor
|
|
21 Sep 2022 |
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
|
|
21 Sep 2022 |
Octagon Therapeutics Enters Inflammation-Focused Research Alliance with Novo Nordisk
|
|
21 Sep 2022 |
Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy
|
|
20 Sep 2022 |
Versantis to be acquired by GENFIT, combining forces to continue the development of its revolutionary therapeutics for patients with liver diseases
|
|
16 Sep 2022 |
Integral Molecular Licenses Claudin 18.2 Monoclonal Antibodies to CARTEXELL for Oncology Cell Therapies
|
|
13 Sep 2022 |
Novo Nordisk and Microsoft collaborate to accelerate drug discovery and development using big data and artificial intelligence
|
|
09 Sep 2022 |
Photys Therapeutics Debuts with $75 Million Series A Funding to Advance New Class of Bifunctional Molecules for Precision Phosphorylation to Modulate and Repair Disease-Driving Proteins
|
|
07 Sep 2022 |
Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche
|
|
07 Sep 2022 |
Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines
|
|
06 Sep 2022 |
PhoreMost enters multi-project drug target discovery collaboration with Roche
|
|
01 Sep 2022 |
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
|
|
23 Aug 2022 |
NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)
|
